Jiangsu Hengrui Medicine's (SHA:600276) subsidiaries, Shandong Shengdi Pharmaceutical and Jiangsu Hengrui Medicine, will conduct clinical trials on HRS-3802 sustained-release tablets after receiving approval from China's National Medical Products Administration, according to a Shanghai Stock Exchange disclosure on Tuesday.
The drug will be tested as a treatment for advanced malignant solid tumors.
The pharmaceutical company invested 10.3 million yuan into the research and development of the drug, the disclosure said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments